Investigating how phospholipids contribute to antifungal drug resistance in a deadly fungus.
Role of phospholipids in antifungal drug resistance in Cryptococcus neoformans
This study is looking at how certain fats in a fungus called Cryptococcus neoformans help it resist antifungal medicines, with the goal of finding better treatments for people with weakened immune systems who are dealing with cryptococcosis.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Rutgers Biomedical and Health Sciences NIH-funded |
| Lab location | 1 site (Newark, UNITED STATES) |
| Project ID | NIH-10883744 on NIH RePORTER |
What this research studies
This research focuses on understanding the role of phospholipids in the resistance of the fungus Cryptococcus neoformans to antifungal drugs. The team is exploring how a specific enzyme, lipid flippase, affects the fungus's ability to resist treatment with echinocandins, a class of antifungal drugs. By studying the genetic and biochemical mechanisms involved, the researchers aim to identify new targets for antifungal therapy. This could lead to more effective treatments for patients suffering from cryptococcosis, particularly those with compromised immune systems.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with cryptococcosis, especially those who are immunocompromised due to conditions like HIV/AIDS.
Not a fit: Patients with fungal infections other than cryptococcosis may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of new antifungal therapies that are more effective and less toxic for patients.
How similar studies have performed: Previous research has shown promise in targeting similar mechanisms of drug resistance in other fungal pathogens, indicating potential for success in this area.
Where this research is happening
Newark, UNITED STATES
- Rutgers Biomedical and Health Sciences — Newark, United States (Active)
Researchers
- Principal investigator: Xue, Chaoyang — Rutgers Biomedical and Health Sciences
- Study coordinator: Xue, Chaoyang
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.